Dr. Michael Wang, DO
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2012
Licensed in California since 2017, according to the Osteopathic Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
CA license 20A15556 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Hospital of Orange County (73 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $143 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $40.14 |
|---|---|
| Qol Medical, LLC | $36.28 |
| Kyowa Kirin, Inc. | $23.52 |
| Mirum Pharmaceuticals, Inc. | $22.80 |
| Rhythm Pharmaceuticals, Inc. | $20.67 |
| Food and Beverage | $143 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $15,691 in research payments for these studies, mostly to the institutions running them.
- Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03196427
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.